These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30136178)

  • 1. Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study.
    Joshi N; Hensen M; Patel S; Xu W; Lasch K; Stolk E
    Pharmacoeconomics; 2019 Jan; 37(1):85-92. PubMed ID: 30136178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom.
    Castejón N; Cappelleri JC; Cuervo J; Lang K; Mehta P; Mokgokong R; Mamolo C
    Health Qual Life Outcomes; 2018 Apr; 16(1):66. PubMed ID: 29669568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health state utilities associated with treatment options for acute myeloid leukemia (AML).
    Matza LS; Deger KA; Howell TA; Koetter K; Yeager AM; Hogge D; Fisher V; Louie AC; Chung KC
    J Med Econ; 2019 Jun; 22(6):567-576. PubMed ID: 30775943
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.
    Stein EM; Yang M; Guerin A; Gao W; Galebach P; Xiang CQ; Bhattacharyya S; Bonifacio G; Joseph GJ
    Health Qual Life Outcomes; 2018 Sep; 16(1):193. PubMed ID: 30241538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
    Ashfaq K; Yahaya I; Hyde C; Andronis L; Barton P; Bayliss S; Chen YF
    Health Technol Assess; 2010 Dec; 14(54):iii-iv, ix-xi, 1-141. PubMed ID: 21138675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health state utilities for beta-thalassemia: a time trade-off study.
    Martin AP; Ferri Grazzi E; Mighiu C; Chevli M; Shah F; Maher L; Shaikh A; Sagar A; Hubberstey H; Franks B; Ramos-Goñi JM; Oppe M; Tang D
    Eur J Health Econ; 2023 Feb; 24(1):27-38. PubMed ID: 35347553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom.
    Aristides M; Barlev A; Barber B; Gijsen M; Quinn C
    Health Qual Life Outcomes; 2015 Nov; 13():181. PubMed ID: 26573610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifying the Composite Time Trade-Off Method to Improve Its Discriminatory Power.
    Jakubczyk M; Lipman SA; Roudijk B; Norman R; Pullenayegum E; Yang Y; Gu NY; Stolk E
    Value Health; 2023 Feb; 26(2):280-291. PubMed ID: 36244905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.
    Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; Isidori A; Sparaventi G; Leoni P
    Leuk Lymphoma; 2006 Jun; 47(6):1091-102. PubMed ID: 16840201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS).
    Matza LS; Phillips GA; Howell TA; Ciffone N; Ahmad Z
    J Med Econ; 2020 Sep; 23(9):978-984. PubMed ID: 32479143
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
    Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
    Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
    Hagiwara M; Sharma A; Chung KC; Delea TE
    J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.
    Lazzarotto D; Candoni A; Nadali G; Pavan L; Lessi F; Mosna F; Simeone E; Ventura G; Gherlinzoni F; Semenzato G; Pizzolo G; Fanin R
    Eur J Haematol; 2016 Jun; 96(6):586-92. PubMed ID: 26186084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active acute leukaemia: should transplant be offered to all patients?
    Avni B; Shapira MY; Resnick IB; Stepensky P; Or R; Grisariu S
    Hematol Oncol; 2017 Dec; 35(4):797-803. PubMed ID: 27338621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.